13-panel through the 18-panel adds each of these specialty analytes one or two at a time. The 19-panel consolidates all of them into a single card, making it the appropriate choice for programs whose monitored population has documented exposure to multiple emerging substances simultaneously and for whom running multiple lower-panel cards is operationally or financially impractical.

Why Do Programs Choose a 19 Panel Drug Test Dip Card Over Lower Panel Counts?

Programs choose the 19 panel drug test dip card when their monitored population has documented exposure to three or more specialty analytes simultaneously, making the per-test cost of the 19-panel more economical than running multiple lower-panel cards, separate specialty strips, or a combination of standard and add-on formats at each monitoring appointment. Running a 13-panel dip card with TRA at $1.29 alongside separate GAB and KET strips to approximate the 19-panel’s coverage costs more in combined per-test pricing, requires more procedural steps, and creates more documentation complexity than a single 19-panel dip at $1.05. The 19-panel is also the only format that includes the ADLTX validity check as a standard built-in feature alongside all specialty analytes, eliminating the need for a separate adulterant protocol. For programs serving populations with complex polysubstance histories, the 19-panel simplifies the monitoring protocol to a single card, single read, and single documentation entry. The SAMHSA 2024 National Survey on Drug Use and Health documents polysubstance use involving three or more substances as the dominant pattern in populations engaged in formal drug treatment, which is precisely the population for whom the 19-panel’s comprehensive coverage provides the greatest monitoring value.

How Does the 19 Panel Dip Card Compare to Running Multiple Smaller Tests?

A program currently running a standard 12-panel dip card alongside separate FEN, GAB, KRA, TRA, and KET strips to approximate the 19-panel’s coverage is conducting a six-device test per collection. This approach costs more per test in combined strip prices, requires more dip steps, creates more result windows to read and document, and introduces more points of error in the collection process. The 19-panel dip card consolidates all of this into a single foil-sealed card, a single 10 to 15 second dip, a single 5-minute read window, and a single documentation entry. For high-volume programs conducting daily or every-other-day collections across 20 or more participants, this consolidation eliminates hours of collective staff time per week. Contact the 12 Panel Now clinical accounts team at 561-897-9238 to request a cost comparison calculation for your current multi-card protocol versus the 19-panel single-card format.

What Is the 19 Panel Drug Test Cost Per Test?

The 19 panel drug test cost starts at $1.05 per test at wholesale for the SM-DOA-6195FUO, making it one of the most cost-efficient comprehensive multi-substance dip cards on the market when evaluated on a per-analyte basis: nineteen drug strips plus three validity markers for $1.05 per test equals less than $0.06 per analyte. For comparison, sourcing each specialty analyte separately via single-panel strips at list prices produces a combined per-test cost well above $1.05 before factoring in the standard 13-panel baseline. The 19-panel’s per-test economics reflect 12 Panel Now’s manufacturer-direct position: because the Serenity brand 19-panel dip card is manufactured in-house rather than resold from a third-party supplier, the cost structure does not include distributor markup. Qualifying bulk orders ship free with same-day dispatch before 3:00 PM EST. Volume pricing tiers are available for orders above 500, 1,000, and 5,000 units. Programs that send a competitor rate sheet for a comparable 19-substance format will receive a guaranteed 10% price match or better.

How Much Does the 19 Panel Dip Card Save Versus Individual Test Strips?

As a reference point, a single-panel FEN strip at 12 Panel Now is available from $0.49 per strip. Adding individually priced GAB, KRA, TRA, and KET strips alongside a base 13-panel dip card at $1.29 produces a combined per-collection cost that exceeds the $1.05 19-panel price even before accounting for the ADLTX validity check. Programs should request a custom quote by contacting [email protected] with their current protocol, current supplier, and monthly volume for a specific cost comparison analysis.

What Is ADLTX on the 19 Panel Drug Test Dip Card?

ADLTX (Adulterant Detection) on the 19 Panel Drug Test Dip Card refers to three built-in specimen validity strips running simultaneously with the drug panel: Specific Gravity, pH, and Creatinine, which detect the most common forms of specimen tampering and flag invalid samples before any drug strip result is interpreted. The Specific Gravity strip detects specimens below 1.003, flagging donors who consumed excessive water to dilute drug metabolite concentrations below detection thresholds. The pH strip detects values outside the 4.5 to 9.0 physiological range, indicating the addition of acidic or alkaline adulterants such as bleach or vinegar to the specimen after collection. The Creatinine strip detects concentrations below 2 mg/dL, the SAMHSA-defined threshold for specimen substitution indicating the sample may be water or a non-urine fluid. The three markers collectively cover the most common specimen tampering methods documented in compliance drug testing literature. The SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs define the thresholds at which each validity marker indicates a dilute, substituted, or adulterated specimen, and the ADLTX strips on the SM-DOA-6195FUO are calibrated to these published SAMHSA thresholds. Programs using the 19-panel eliminate the need to run a separate ADLTX strip alongside their drug panel, reducing both cost and procedural complexity at every collection.

Does the 19 Panel Dip Card Pass Muster for Court-Ordered and Legal Compliance Settings?

The 19 Panel Dip Card (SM-DOA-6195FUO) is classified Forensic Use Only and is appropriate for court-ordered drug testing, probation monitoring, correctional facility testing, non-DOT employer programs, and other legal compliance settings that do not require CLIA Waived classification. All presumptive positive results on any strip of the 19-panel dip card must be confirmed by GC-MS or LC-MS/MS laboratory analysis before any legal action, probation violation, or employment consequence is taken, consistent with SAMHSA confirmation requirements for all rapid immunoassay screening results. For clinical settings requiring CLIA Waived classification, contact the 12 Panel Now clinical team at 561-897-9238 to discuss CLIA Waived configuration availability at the 19-panel analyte level.

Who Uses the 19 Panel Drug Test Dip Card?

The 19 panel drug test dip card is used by comprehensive addiction treatment programs managing populations with complex polysubstance histories, by pain management programs prescribing multiple monitored analgesics alongside fentanyl screening, by drug courts and probation programs with documented exposure to multiple emerging substances across their caseload, by correctional health departments needing maximum analyte coverage in a single dip card, and by any program that has outgrown lower panel formats and needs to consolidate multiple separate tests into one card without building a custom configuration. Residential treatment centers in areas with complex drug markets where gabapentin, kratom, tramadol, and ketamine are all documented in patient intake assessments adopt the 19-panel as their standard monitoring format because it eliminates the need to make ongoing decisions about which specialty strips to include at each monitoring cycle. Methadone clinics and buprenorphine programs in urban markets where the full spectrum of opioid-adjacent substances is documented in patient intake data use the 19-panel to maintain comprehensive visibility without managing multiple card types in their supply inventory. Employers in safety-sensitive industries who have identified multiple emerging substance concerns in their workforce adopt the 19-panel for post-incident and reasonable-suspicion testing where maximum analyte coverage in a single test is required.

Is the 19 Panel Drug Test Dip Card Right for Comprehensive Addiction Treatment Programs?

For residential and intensive outpatient addiction treatment programs, the 19-panel provides comprehensive baseline monitoring without requiring staff to select between multiple card types at each collection. A program managing 30 or more clients with varying substance use histories benefits from a single card format that covers all documented emerging substances simultaneously rather than maintaining inventory of multiple panel configurations and making per-client decisions about which analytes to test. The SAMHSA National Helpline and NIDA treatment research resources consistently document polysubstance use as the dominant pattern in treatment-engaged populations, reinforcing the clinical rationale for the 19-panel’s comprehensive analyte coverage over lower-panel options. The 19-panel’s $1.05 price point makes it cost-competitive with running a 13-panel plus specialty strips for the most common emerging analytes in treatment populations.

Does the 19 Panel Drug Test Dip Card Detect All Emerging Substances?

The 19 panel drug test dip card covers the six primary emerging analytes that standard panels miss (GAB, TRA, KET, KRA, FEN, ETG) alongside the complete 13-substance standard baseline and ADLTX validity checking, but it does not detect xylazine, tianeptine (ZAZA), K2/synthetic cannabinoids, psilocybin, LSD, delta-8 THC, 6-MAM (heroin marker), or other substances outside its nineteen drug strips. Xylazine, the veterinary sedative that is the subject of active federal emergency health responses and increasingly documented as a fentanyl supply adulterant in multiple US cities, requires a dedicated XYL strip not present in the standard SM-DOA-6195FUO format. The HHS xylazine emergency response documentation identifies xylazine as a priority emerging substance in the ongoing overdose crisis. Tianeptine (ZAZA), a non-controlled imported compound with opioid-like properties at high doses that has been documented in overdose data across multiple states, requires a TIA strip. Synthetic cannabinoids (K2/Spice) require a dedicated K2 strip available at the 16-panel K2 configuration. Programs whose monitored populations have documented xylazine or tianeptine exposure should contact 12 Panel Now to discuss custom panel configurations that add these analytes to the 19-panel baseline. The complete dip card product category at 12 Panel Now lists all available configurations including custom options above the 19-panel tier.

19 Panel Drug Test Dip Card vs 19 Panel Drug Test Cup

The 19 panel drug test dip card and the 19 panel drug test cup detect equivalent substances at the same immunoassay accuracy, with the dip card (SM-DOA-6195FUO) at $1.05 offering a substantially lower per-test cost than comparable 19-panel cup configurations, while the cup format provides integrated specimen collection, built-in temperature verification, and tamper-evident chain-of-custody design for settings where those features are required. For residential treatment centers and sober living homes conducting daily monitoring under staff supervision, the dip card’s $1.05 per-test price for nineteen substances plus ADLTX provides exceptional value at high monitoring frequency. For probation departments and drug courts requiring observed collection documentation with temperature strip verification and sealed click-top lid design, the cup format remains the appropriate choice regardless of per-test cost difference. Both formats are available at 12 Panel Now at manufacturer-direct pricing. Browse the full 19 panel drug test product category at 12 Panel Now for complete configuration comparison.

Buying 19 Panel Drug Test Dip Cards in Bulk

At 12 Panel Now, the 19 panel drug test bulk and 19 panel drug test wholesale pricing starts from $1.05 per test for the SM-DOA-6195FUO (GAB+KET+TRA+FEN+ETG+KRA+ADLTX) format, with same-day shipping before 3:00 PM EST and free shipping on qualifying bulk orders. As the US-based manufacturer of the Serenity brand drug testing product line, 12 Panel Now maintains over 15 million products in stock with no backorders across all 19-panel dip card configurations. Each card is individually foil-sealed with an 18 to 24 month shelf life. Store between 36 and 86 degrees Fahrenheit away from direct sunlight and humidity. The BUP strip at 10 ng/mL and the FEN strip at 20 ng/mL are the most analytically sensitive strips on the panel and benefit most from temperature-controlled bulk storage for large volume orders. Send a competitor rate sheet and 12 Panel Now beats it by 10% guaranteed. OEM, private label, and custom configurations adding xylazine, tianeptine, K2, or other emerging analytes to the 19-panel baseline are available. Contact the wholesale team at 561-897-9238 or [email protected].

19 Panel Drug Test Dip Cards at 12 Panel Now (Serenity Drug Test / Slash Medical), 801 N Congress Ave, Boynton Beach FL 33426. Manufacturer of the Serenity brand drug testing product line. Key product: SM-DOA-6195FUO (19 Panel FUO, AMP/BAR/BUP/BZO/COC/ETG/FEN/GAB/KET/KRA/MDMA/MET/MTD/OPI/OXY/PCP/TRA/THC + 3 ADLTX, from $1.05 at /product/19-panel-dip-card-gaba-fen-spice-k2-mdpv-bath-salts/). Regulatory references: SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs 2025. HHS fentanyl authorization effective July 7, 2025. HHS xylazine emergency response. FDA esketamine (Spravato) approval. DEA ketamine Schedule III documentation. NIH ketamine pharmacology research. NIH tramadol clinical pharmacology. SAMHSA 2024 National Survey on Drug Use and Health. NIDA treatment research resources. SAMHSA National Helpline. OSHA Drug-Free Workplace guidelines.